New York City, New York Aug 15, 2021 (Issuewire.com) - Conventional drug research and development mainly focuses on directly regulating the activity of proteins or enzymes to treat diseases. PROTAC, a novel technology born in 2001, takes advantage of the "cleaner" in the cell—the ubiquitin-proteasome system to selectively degrade the pathogenic proteins to treat cancers and other hard-to-treat diseases. With expertise in protein degradation, Creative Biolabs established a solution center focused on the discovery, development, and overall assessment of PROTAC molecules.
The discovery solution allows for the one-stop development of desired PROTAC molecules, ranging from ligand design for the target (nuclear receptors, protein kinases, regulatory proteins, etc.), ligand screening for E3 ligase (VHL PROTAC, cIAP PROTAC, cereblon PROTAC, etc.), structural modification, to peptide and compound synthesis.
"During the one-stop solutions, required substances such as linkers and interested proteins can be provided by our clients, or from our in-stock products, or clients can entrust us to develop whatever is required," said a technician.
Featured technology platforms adopted at Creative Biolabs:
* Homo-PROTAC platform
* HaloPROTAC
* ATTEC
An artificially developed PROTAC molecule needs to undergo a series of in vitro and in vivo assessments to testify its efficacy and safety, so that it is viable to enter the subsequent clinical trials. At Creative Biolabs, solubility and chemical stability, cell permeability efficacy, and other efficacy factors can be evaluated through in vitro assays. Holding expertise in establishing animal models, Creative Biolabs provides the evaluation of acute toxicity for PROTAC and ADME assessment for PROTAC, which are indispensable tests to verify the safety, pharmacokinetics, and metabolism of drug exposure, and thereby offer guidance in lead candidate selection, lead optimization, preclinical testing, and clinical trials.
PROTAC-based drugs are gaining more shares in the market of protein degradation therapies, which are advantageous in the following aspects.
* Degrade the pathogenic proteins.
* Low dosage required.
* Reduced toxicity.
* Point at undruggable targets (proteins).
* Lingered pharmacodynamics effect.
For this fully potential candidate, Creative Biolabs is continually expanding its service capabilities, aiming to support the study in a more efficient and economical manner.
Visit https://www.creative-biolabs.com/protac/ to learn more.
About
Creative Biolabs gathers a group of professional researchers who are dedicated to the R&D of protein degradation therapy. Through the team's relentless exploration, the company provides the entire one-stop PROTAC-based drug development services from early discovery to pre-clinical evaluation, aiming to support global clients' research projects in pharmaceutical, academic, and industrial areas.
Media Contact
Candy Swift marketing@creative-biolabs.com https://www.creative-biolabs.com/protac/
